Anadys Pharmaceuticals (ANDS) Reports Positive Data for Setrobuvir in Phase 2b Hepatitis C Study

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today released interim antiviral response and safety data from an ongoing Phase IIb study of setrobuvir in combination with pegylated interferon and ribavirin (P/R) in genotype 1 hepatitis C patients. Setrobuvir is the Company's direct-acting antiviral being developed for the treatment of chronic hepatitis C, or HCV.

"We are pleased with today's data, which we believe demonstrate a compelling profile for setrobuvir in significantly more patients," said Steve Worland, Ph.D., President and CEO of Anadys. "The antiviral response in patients who had failed prior treatment is a particularly encouraging benchmark of setrobuvir's potency and high barrier to resistance. Coupled with a favorable safety profile to date, we believe today's data position setrobuvir as a very attractive agent to be included in future DAA combination regimens."

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• YS Biopharma (YS) Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
• Moleculin Biotech (MBRX) Announces EMA Grants Orphan Drug Designation for Treatment of Acute Myeloid Leukemia
• Ocular Therapeutix (OCUL) Reports Positive Topline Phase 1 Data for AXPAXLI